We at Taj Pharma intend to make our manufacturing systems comply with the requirements of the FDA (cGMP) such that pilot plant scale production of products in the stage of clinical development or for use in clinical studies, as well as manufacture of products in small lots are practicable to ensure a highly stable pharmaceuticals formulations of generic equivalent and bio-similar products. We conduct extensive bio-similar and bio-equivalency studies for all our formations in order to obtain better shelf life, absorption and excellent quality of our generic formulation.
